Is INBX or APGE more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Apogee Therapeutics N/A -32.64% -31.25%

Does the media favor INBX or APGE?

In the previous week, Apogee Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for Apogee Therapeutics and 2 mentions for Inhibrx Biosciences. Apogee Therapeutics' average media sentiment score of 0.81 beat Inhibrx Biosciences' score of 0.62 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, INBX or GRFS?

Grifols has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibrx Biosciences $1.30M 1,050.71 -$140.05M -$8.39 N/A Grifols $8.51B 0.61 $454.82M $0.19 39.95

Does the media favor INBX or CRSP?

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 2 mentions for Inhibrx Biosciences. CRISPR Therapeutics' average media sentiment score of 0.85 beat Inhibrx Biosciences' score of 0.62 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media prefer INBX or XENE?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Inhibrx Biosciences' score of 0.62 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or INBX more profitable?

CG Oncology's return on equity of -23.33% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Inhibrx Biosciences N/A -563.90% -72.32%

Does the media prefer CGON or INBX?

In the previous week, CG Oncology had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for CG Oncology and 2 mentions for Inhibrx Biosciences. CG Oncology's average media sentiment score of 1.08 beat Inhibrx Biosciences' score of 0.62 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibrx Biosciences (INBX) Competitors

$93.11 -0.40 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$92.91 -0.20 (-0.21%)

As of 05:26 PM Eastern

Compare

INBX vs. APGE, GRFS, CRSP, XENE, and CGON

Should you buy Inhibrx Biosciences stock or one of its competitors? MarketBeat compares Inhibrx Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibrx Biosciences include Apogee Therapeutics (APGE), Grifols (GRFS), CRISPR Therapeutics (CRSP), Xenon Pharmaceuticals (XENE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Inhibrx Biosciences compare to Apogee Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inhibrx Biosciences currently has a consensus target price of $150.00, indicating a potential upside of 61.10%. Apogee Therapeutics has a consensus target price of $114.56, indicating a potential upside of 34.40%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Inhibrx Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

In the previous week, Apogee Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for Apogee Therapeutics and 2 mentions for Inhibrx Biosciences. Apogee Therapeutics' average media sentiment score of 0.81 beat Inhibrx Biosciences' score of 0.62 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,050.71	-$140.05M	-$8.39	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Apogee Therapeutics' return on equity of -32.64% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Summary

Apogee Therapeutics beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Grifols?

Inhibrx Biosciences (NASDAQ:INBX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Grifols has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,050.71	-$140.05M	-$8.39	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	39.95

Grifols has a net margin of 5.54% compared to Inhibrx Biosciences' net margin of 0.00%. Grifols' return on equity of 6.21% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Grifols	5.54%	6.21%	2.39%

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 61.10%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 31.75%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Inhibrx Biosciences had 2 more articles in the media than Grifols. MarketBeat recorded 2 mentions for Inhibrx Biosciences and 0 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat Inhibrx Biosciences' score of 0.62 indicating that Grifols is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Positive
Grifols	Very Positive

Summary

Inhibrx Biosciences beats Grifols on 9 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 2 mentions for Inhibrx Biosciences. CRISPR Therapeutics' average media sentiment score of 0.85 beat Inhibrx Biosciences' score of 0.62 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,050.71	-$140.05M	-$8.39	N/A
CRISPR Therapeutics	$3.51M	1,429.44	-$581.60M	-$6.22	N/A

Inhibrx Biosciences presently has a consensus price target of $150.00, suggesting a potential upside of 61.10%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 30.29%. Given Inhibrx Biosciences' higher possible upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Inhibrx Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

CRISPR Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Xenon Pharmaceuticals?

Inhibrx Biosciences (NASDAQ:INBX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Inhibrx Biosciences currently has a consensus price target of $150.00, suggesting a potential upside of 61.10%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 48.49%. Given Inhibrx Biosciences' higher probable upside, equities research analysts plainly believe Inhibrx Biosciences is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inhibrx Biosciences has higher earnings, but lower revenue than Xenon Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,050.71	-$140.05M	-$8.39	N/A
Xenon Pharmaceuticals	$7.50M	670.12	-$345.91M	-$4.70	N/A

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Inhibrx Biosciences' score of 0.62 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Xenon Pharmaceuticals' return on equity of -49.23% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Summary

Xenon Pharmaceuticals beats Inhibrx Biosciences on 10 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Inhibrx Biosciences has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,316.01	-$160.99M	-$2.33	N/A
Inhibrx Biosciences	$1.30M	1,050.71	-$140.05M	-$8.39	N/A

In the previous week, CG Oncology had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for CG Oncology and 2 mentions for Inhibrx Biosciences. CG Oncology's average media sentiment score of 1.08 beat Inhibrx Biosciences' score of 0.62 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology's return on equity of -23.33% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

CG Oncology has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market.

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 35.58%. Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 61.10%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CG Oncology beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.37B	$3.37B	$6.45B	$12.20B
Dividend Yield	N/A	2.25%	2.66%	5.66%
P/E Ratio	N/A	19.64	23.92	24.34
Price / Sales	1,050.71	306.08	517.49	135.40
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	169.29	8.00	10.50	6.70
Net Income	-$140.05M	$23.89M	$3.56B	$337.21M
7 Day Performance	4.50%	0.88%	0.18%	1.78%
1 Month Performance	-14.29%	-0.39%	1.53%	3.64%
1 Year Performance	536.87%	43.71%	24.25%	28.19%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	2.214 of 5 stars	$93.11 -0.4%	$150.00 +61.1%	+541.8%	$1.37B	$1.30M	N/A	166	News Coverage Positive News Analyst Upgrade Gap Up
APGE Apogee Therapeutics	3.248 of 5 stars	$85.00 +2.4%	$114.56 +34.8%	+93.8%	$5.14B	N/A	N/A	91
GRFS Grifols	4.6229 of 5 stars	$7.34 +0.1%	$10.00 +36.2%	-14.1%	$4.99B	$8.51B	38.63	25,247	Positive News
CRSP CRISPR Therapeutics	3.503 of 5 stars	$51.48 -0.2%	$65.47 +27.2%	+27.2%	$4.98B	$3.51M	N/A	460	Analyst Downgrade
XENE Xenon Pharmaceuticals	3.5807 of 5 stars	$52.79 +3.1%	$77.20 +46.2%	+60.0%	$4.95B	$7.50M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. APGE, GRFS, CRSP, XENE, and CGON

How does Inhibrx Biosciences compare to Apogee Therapeutics?

Summary

How does Inhibrx Biosciences compare to Grifols?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Summary

How does Inhibrx Biosciences compare to Xenon Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. APGE, GRFS, CRSP, XENE, and CGON

How does Inhibrx Biosciences compare to Apogee Therapeutics?

Do institutionals and insiders believe in INBX or APGE?

Do analysts rate INBX or APGE?

Which has more volatility and risk, INBX or APGE?

Does the media favor INBX or APGE?

Which has higher earnings and valuation, INBX or APGE?

Is INBX or APGE more profitable?

Summary

How does Inhibrx Biosciences compare to Grifols?

Which has preferable valuation & earnings, INBX or GRFS?

Is INBX or GRFS more profitable?

Do analysts rate INBX or GRFS?

Do institutionals & insiders hold more shares of INBX or GRFS?

Which has more volatility & risk, INBX or GRFS?

Does the media favor INBX or GRFS?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Do institutionals and insiders hold more shares of INBX or CRSP?

Does the media favor INBX or CRSP?

Which has stronger earnings and valuation, INBX or CRSP?

Do analysts rate INBX or CRSP?

Which has more risk and volatility, INBX or CRSP?

Is INBX or CRSP more profitable?

Summary

How does Inhibrx Biosciences compare to Xenon Pharmaceuticals?

Do analysts rate INBX or XENE?

Do insiders & institutionals have more ownership in INBX or XENE?

Which has better earnings & valuation, INBX or XENE?

Does the media prefer INBX or XENE?

Which has more volatility & risk, INBX or XENE?

Is INBX or XENE more profitable?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Which has higher valuation & earnings, CGON or INBX?

Does the media prefer CGON or INBX?

Is CGON or INBX more profitable?

Which has more risk and volatility, CGON or INBX?

Do analysts prefer CGON or INBX?

Do institutionals & insiders hold more shares of CGON or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools